KEYTRUDA is indicated for the treatment of patients with metastatic small cell lung cancer (SCLC) with
disease progression on or after platinum-based chemotherapy and at least one other prior line of therapy.
Treatment with Keytruda continued until documented
disease progression, unacceptable toxicity or a maximum of 24 months.
The median time with no
disease progression in Calquence patients has not yet been reached in the study, versus 16.5 months in the control.
Feng et al., "Downregulated miR-33b is a novel predictor associated with
disease progression and poor prognosis in multiple myeloma," Leukemia Research, vol.
Of those, 108 patients who had at least three months of follow-up documented in the medical record and at least one episode of
disease progression on ET were selected for analysis.
Skeletal
disease progression lesions were detected in 40 of 50 (80%) cases, and in 10 (20%) cases local metastatic process was confirmed histologically after salvage surgery or biopsy.
"Although this was a Phase 1 trial, and functional outcome data were collected for the purpose of assessing safety, we performed secondary analyses of these data as a means to gain insight into how cellular transplantation affected
disease progression rates and to inform outcome assessment approaches in future trial phases," said Eva Feldman, director of the A.
Effect of micronutrient supplementation on
disease progression in asymptomatic, antiretroviral-naive, HIV infected adults in Botswana: a randomized clinical trial.
We also need alternative approaches to treatment, This study is important because it begins to explain how THC can influence
disease progression in SIV-infected macaques.
Among all patients combined, factors significantly associated with renal
disease progression included having diabetes (hazard ratio, 1.96), hypertension (HR, 1.50), heart failure (HR, 1.39), previous hospitalizations (HR, 1.33), and being female (HR, 1.49) and older (HR, 1.03).
Limited studies previously carried out with this patient population have identified several viral, genetic, and immunologic factors that are associated with rapid
disease progression, such as the early emergence of CXCR4-utilizing HIV strains, risk single-nucleotide polymorphisms (SNPs) [3] within interleukin-7R[alpha] or Toll-like receptor loci, and high concentrations of IP-10 (interferon [gamma] induced protein) in the plasma (3-7).
Results could reveal how CF develops, which in turn could lead to interventions that delay or prevent
disease progression. The studies also could provide critical information to help resolve competing theories on the origin and progression of CF-associated abnormalities.
